BHC Bausch Health Companies Inc. Insider Trading

Paulson & Co. increases BHC stake by 2,500,000 shares ($15.6M) to 73,255,869 shares; stock down 24.9% from 52-week high but up 7.6% in 30 days.

Paulson & Co., a 10% shareholder of Bausch Health Companies Inc., purchased 2,500,000 shares at $6.25 on 2025-11-25, raising its total holdings to 73,255,869 shares (a +3.5% increase). The stock is currently at $6.35, down 24.9% from its 52-week high of $8.46 but has rebounded 7.6% over the past 30 days, suggesting recent stabilization. Bausch Health trades at a P/E of 6.48 with positive quarterly net income of $179,000,000, though full-year results showed a loss, indicating a transitional financial profile. Paulson's cross-ticker track record shows 3 prior open-market buys with a 90-day average return of +34.1% and a 50% win rate, providing relevant context for evaluating the conviction behind this accumulation in a deeply discounted name.

Director Paulson John purchased 34,721,118 shares of BHC for $312,490,062 on 2025-08-14, doubling holdings to 70,755,869 shares

Paulson John, a director, executed a substantial open-market purchase of 34,721,118 shares at $9.00 per share, totaling $312,490,062, raising his holdings from 36,034,751 to 70,755,869 shares (+96.4%) on 2025-08-14. This transaction occurred alongside two consecutive prior buys at BHC on 2025-08-13 and 2025-08-12, as well as earlier purchases on 2025-06-13 and 2025-06-12, indicating a concentrated accumulation pattern within a narrow window. The purchase price of $9.00 sits near the 52-week high of $9.78 and notably above the current price of $7.51 (-23.2% from 52-week high), meaning the position has declined in value since execution. Against this, the insider's cross-ticker track record shows 7 prior buys with an average 30-day return of +19.8%, though measurable same-ticker outcomes at BHC remain limited (most recent trades at this ticker lack 90-day return data; only June purchases show 30-day returns of +8.1% and +17.4%).

Director Paulson buys 3.24M shares at blended $6.56 across 3 days, raising stake by 9.9% to $21.3M total investment.

Paulson John, a Director, executed 3 separate purchases totaling 3,243,049 shares for $21,267,730.74 ($21.3M) over August 11–13, 2025, at prices ranging from $6.35 to $7.06. This expanded his holdings from 32,791,702 to 36,034,751 shares—a +9.9% increase in stake. The timing coincides with stock recovery: Bausch Health trades at $7.17, down 26.7% from its 52-week high of $9.78 but up 13.1% over the prior 30 days and 55.9% over 90 days. In his same-ticker history at BHC, Paulson's four prior buys in June 2025 generated 30-day returns ranging from +8.1% to +31.1%, though none have yet reached 90-day measurable outcomes. Across his broader cross-ticker track record, prior open-market buys averaged +19.8% 30-day returns. The company's fundamentals show near-breakeven profitability (net income of $148.0M on $2.5B quarterly revenue, but full-year negative net income), a P/E of 26.56, and 9.9% annual revenue growth—a backdrop of mixed signals where the director is accumulating at depressed price levels relative to recent highs.

Director Paulson John purchases 3,564,059 shares of BHC at $5.94, adding $21.2M to 32.79M-share stake

Paulson John, a director of Bausch Health Companies Inc., purchased 3,564,059 shares at $5.94 on 2025-06-13, increasing his holdings by 12.2% to 32,791,702 shares post-transaction. This represents a $21,170,510.46 capital commitment. The transaction occurs in the context of a company carrying negative annual net income of $-58,000,000.00, though the firm has posted annual revenue growth of +9.9%. At the transaction price of $5.94, the stock has since declined -41.4% from its 52-week high of $9.78, though it has risen +22.7% over the prior 30 days. Notably, three additional BHC purchases by this director occurred on consecutive trading days immediately preceding this filing (2025-06-10, 2025-06-11, 2025-06-12), establishing a pattern of sustained accumulation. His cross-ticker track record shows 3 prior buys, but timing outcomes from those trades are not yet calculable for this new position.

Director Paulson John bought 2,788,608 shares of BHC across 3 transactions for $14,700,256.94 on 2025-06-10 through 2025-06-12.

Director Paulson John executed 3 separate purchases totaling 2,788,608 shares for $14,700,256.94 (blended average $5.27) between June 10–12, 2025, expanding his holdings by 10.5% to 29,227,643 shares. The timing is notable: the purchases occurred near the bottom of a 52-week range ($4.32–$9.78), with the stock trading 43.7% below its 52-week high. The company is unprofitable (net income $-58,000,000 in the latest quarter; full-year net income was negative), though revenue grew 9.9% year-over-year. The multi-day, multi-tranche structure and substantial capital commitment of $14.7M suggest deliberate, incremental accumulation at depressed valuations following recent downward price pressure (90-day decline of 22.9%).